HANAMI Kentaro 花見健太郎

Researcher Number	50441853
Affiliation *help	2014 – 2016 : 産業医科大学, 医学部, 助教 2008 – 2009 : 産業医大, 医学部, 研究員 2008 : University of Occupational and Environmental Health, Japan, 医学部, 専門修練医 2007 : 産業医科大学, 医学部, 助教
Review Section/Research Field	Principal Investigator Collagenous pathology/Allergology / 膠原病・アレルギー・感染症内科学
Keywords	Principal Investigator 樹状細胞 / 破骨細胞 / stat6 / シグナル伝達 / ドパミン受容体シグナル / 骨リモデリング / Jak3 / 抗原提示能 / 神経伝達物質

関節炎病態における樹状細胞由来破骨細胞の作用メカニズムの解明Principal InvestigatorOngoing
- Principal Investigator
  
  花見健太郎
- Project Period (FY)
  2016 – 2018
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Collagenous pathology/Allergology
- Research Institution
  University of Occupational and Environmental Health, Japan
Dopamine receptor signaling regulates human osteoclastogenesis.Principal Investigator
- Principal Investigator
  
  HANAMI Kentaro
- Project Period (FY)
  2014 – 2015
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Collagenous pathology/Allergology
- Research Institution
  University of Occupational and Environmental Health, Japan
樹状細胞Stat6制御による新規関節リウマチの治療の開発Principal Investigator
- Principal Investigator
  
  花見健太郎
- Project Period (FY)
  2008 – 2009
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  膠原病・アレルギー・感染症内科学
- Research Institution
  University of Occupational and Environmental Health, Japan

All 2016 2015 2014

All Journal Article Presentation

[Journal Article] Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.2016
- Author(s)
  Hirata S, Li W, Kubo S, Fukuyo S, Mizuno Y, Hanami K, Sawamukai N, Yamaoka K, Saito K, Defranoux NA, Tanaka Y.
- Journal Title
  
  Mod Rheumatol
  
  Volume : 26 Pages : 850-856
- Peer Reviewed / Open Access / Acknowledgement Compliant / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K08956, KAKENHI-PROJECT-16K09915
[Journal Article] Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.2016
- Author(s)
  Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, Hanami K, Saito K, Tanaka Y.
- Journal Title
  
  Ann Rheum Dis.
  
  Volume : 75(7) Pages : 1321-7
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K09915, KAKENHI-PROJECT-26860764
[Journal Article] Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.2016
- Author(s)
  Hirata S, Li W, Kubo S, Fukuyo S, Mizuno Y, Hanami K, Sawamukai N, Yamaoka K, Saito K, Defranoux NA, Tanaka Y.
- Journal Title
  
  Mod Rheumatol.
  
  Volume : Mar 30 Pages : 1-7
- Data Source
  KAKENHI-PROJECT-26860764
[Journal Article] Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.2015
- Author(s)
  Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K.
- Journal Title
  
  Ann Rheum Dis.
  
  Volume : 74(2) Pages : 389-95
- Peer Reviewed / Open Access / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-26860764, KAKENHI-PROJECT-25460713
[Journal Article] Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab.2015
- Author(s)
  Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y.
- Journal Title
  
  Arthritis Res Ther.
  
  Volume : 17 Pages : 280-280
- Peer Reviewed / Open Access / Acknowledgement Compliant / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-25460713, KAKENHI-PROJECT-26860764
[Journal Article] Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.2014
- Author(s)
  Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H.
- Journal Title
  
  Mod Rheumatol.
  
  Volume : 24(3) Pages : 399-404
- Peer Reviewed / Open Access / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-26860764
[Journal Article] Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.2014
- Author(s)
  Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.
- Journal Title
  
  Mod Rheumatol.
  
  Volume : 24(3) Pages : 405-9
- Peer Reviewed / Open Access / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-26860764
[Presentation] Serum 14-3-3η is a Modifiable, Mechanistic Biomarker that Predicts Tocilizumab Response2015
- Author(s)
  Kentaro Hanami, Shintaro Hirata, Anthony Marotta, Yoshiya Tanaka
- Organizer
  欧州リウマチ学会 (第16回)
- Place of Presentation
  ローマ（イタリア）
- Year and Date
  2015-06-10
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26860764
[Presentation] 関節リウマチに対するTocilizumabとAdalimumab投与によるMBDAスコアの12バイオマーカーの挙動比較2015
- Author(s)
  花見健太郎 , 平田信太郎 , 宮川一平 , 久保智史 , 福與俊介 , 澤向範文 , 中野和久 , 中山田真吾 , 齋藤和義 , 田中良哉
- Organizer
  日本リウマチ学会 (第59回)
- Place of Presentation
  名古屋国際会議場（愛知県・名古屋市）
- Year and Date
  2015-04-23
- Data Source
  KAKENHI-PROJECT-26860764
[Presentation] 血清14-3-3ηと関節リウマチの疾患活動性の関連についての検討2015
- Author(s)
  花見健太郎 , 平田信太郎 , 宮川一平 , 久保智史 , 福與俊介 , 澤向範文 , 中野和久 , 中山田真吾 , 齋藤和義 , 田中良哉
- Organizer
  日本リウマチ学会 (第59回)
- Place of Presentation
  名古屋国際会議場（愛知県・名古屋市）
- Year and Date
  2015-04-23
- Data Source
  KAKENHI-PROJECT-26860764

1. 久保智史 (70461548)

# of Collaborated Projects : 1results

# of Collaborated Products : 2results
2. HIRATA Shintaro

# of Collaborated Projects : 0results

# of Collaborated Products : 3results

HANAMI Kentaro 花見 健太郎

Research Projects

Research Products

Co-Researchers

関節炎病態における樹状細胞由来破骨細胞の作用メカニズムの解明Principal InvestigatorOngoing

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Dopamine receptor signaling regulates human osteoclastogenesis.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

樹状細胞Stat6制御による新規関節リウマチの治療の開発Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.2016

Author(s)

Journal Title

Data Source

[Journal Article] Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.2016

Author(s)

Journal Title

Data Source

[Journal Article] Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.2016

Author(s)

Journal Title

Data Source

[Journal Article] Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.2015

Author(s)

Journal Title

Data Source

[Journal Article] Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab.2015

Author(s)

Journal Title

Data Source

[Journal Article] Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.2014

Author(s)

Journal Title

Data Source

[Journal Article] Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.2014

Author(s)

Journal Title

Data Source

[Presentation] Serum 14-3-3η is a Modifiable, Mechanistic Biomarker that Predicts Tocilizumab Response2015

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

[Presentation] 関節リウマチに対するTocilizumabとAdalimumab投与によるMBDAスコアの12バイオマーカーの挙動比較2015

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

[Presentation] 血清14-3-3ηと関節リウマチの疾患活動性の関連についての検討2015

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

HANAMI Kentaro 花見健太郎